… Semaglutide 2·4 mg once weekly, an anti-obesity medication now submitted to regulators
across … Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (…

… semaglutide as the first anti-obesity drug shown to decrease CV events in subjects with
obesity and prevalent CV … The mechanisms whereby semaglutide decreased CV outcomes are …

… OW semaglutide compared with placebo was associated with a consistent reduction in CV
outcomes … those without vascular disease, and a 3.5 times greater risk of expanded composite …

… Secondary kidney outcomes in these cardiovascular outcome … of semaglutide in SUSTAIN
6 and liraglutide in LEADER, compared with placebo, on clinically important kidney outcomes, …

… semaglutide. Therefore, the aim of our study was to first evaluate the antiobesity effect of
semaglutide … , exenatide and semaglutide in the overweight/obese without diabetes in terms of …

… in Patients With Overweight or Obesity) with semaglutide 2.4 mg SQ … not clear whether these
trials will demonstrate improved cardiovascular outcomes, given the potential for an obesity …

… derived outcomes from liraglutide effect and action in diabetes: evaluation … cardiovascular
outcome results and semaglutide and cardiovascular outcomes in patients with type 2 diabetic …

… Like SUSTAIN-6, PIONEER 6 was designed to exclude an 80% excess in CV risk for oral
semaglutide compared with placebo, with an upper limit of the two-sided 95% CI not exceeding …

… Fatal AE incidence was similar between semaglutide and … adverse cardiovascular events
with subcutaneous semaglutide … Cardiovascular outcomes for patients at high cardiovascular …

… and semaglutide consistently reduced major CV outcomes in patients with and without …
the impact of microvascular disease in type 2 diabetes on CV risk, and this study represents an …